Patents by Inventor Lawrence J. D'Souza

Lawrence J. D'Souza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GIP analog and hybrid polypeptides with selectable properties
    Patent number: 8263545
    Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: September 11, 2012
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Odile Esther Levy, Alain D. Baron, Lawrence J. D'Souza, Mary Erickson, Soumitra S. Ghosh, Michael R. Hanley, Samuel Janssen, Carolyn M. Jodka, Diana Y. Lewis, Christine M. Mack, David G. Parkes, Richard A. Pittner, Christopher J. Soares, Ved Srivastava, Andrew A. Young, Thao Le
  • Hybrid polypeptides having glucose lowering activity
    Patent number: 8076288
    Abstract: The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
    Type: Grant
    Filed: August 17, 2005
    Date of Patent: December 13, 2011
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Odile Esther Levy, Michael R. Hanley, Carolyn M. Jodka, Diana Y. Lewis, Christopher J. Soares, Soumitra S. Ghosh, Lawrence J. D'Souza, David G. Parkes, Christine M. Mack
  • DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties
    Publication number: 20110136737
    Abstract: The Present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
    Type: Application
    Filed: August 17, 2007
    Publication date: June 9, 2011
    Applicant: AMYLIN PHARMACEUTICALS, INC.
    Inventors: Odile Esther Levy, Alain D. Baron, Lawrence J. D'Souza, Mary Erickson, Soumitra S. Ghosh, Michael R. Hanley, Samuel Janssen, Carolyn M. Jodka, Diana Y. Lewis, Christine M. Mack, David G. Parkes, Richard A. Pittner, Christopher J. Soares, Ved Srivastava, Andrew A. Young, Thao Le
  • Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same
    Publication number: 20100292172
    Abstract: Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.
    Type: Application
    Filed: May 21, 2010
    Publication date: November 18, 2010
    Applicant: AMYLIN PHARMACEUTICALS, INC.
    Inventors: SOUMITRA S. GHOSH, JOSUE ALFARO-LOPEZ, LAWRENCE J. D'SOUZA, ODILE ESTHER LEVY, QING LIN, CHRISTOPHER J. SOARES
  • PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME
    Publication number: 20100286365
    Abstract: Peptide-peptidase inhibitor conjugate molecules and methods of manufacture thereof are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.
    Type: Application
    Filed: September 26, 2008
    Publication date: November 11, 2010
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Soumitra S. Ghosh, Josue Alfaro-Lopez, Lawrence J. D'Souza, Odile Esther Levy, Qing Lin, Christopher J. Soares
  • Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
    Patent number: 7723471
    Abstract: The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.
    Type: Grant
    Filed: December 12, 2005
    Date of Patent: May 25, 2010
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Odile Esther Levy, Carolyn M. Jodka, Soumitra S. Ghosh, David G. Parkes, Richard A. Pittner, Lawrence J. D'Souza, John S. Ahn, Kathryn S. Prickett, Jonathan David Roth, Sean H. Adams
  • PANCREATIC POLYPEPTIDE FAMILY MOTIFS, POLYPEPTIDES AND METHODS COMPRISING THE SAME
    Publication number: 20100099619
    Abstract: The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.
    Type: Application
    Filed: December 17, 2009
    Publication date: April 22, 2010
    Applicant: AMYLIN PHARMACEUTICALS, INC.
    Inventors: Odile Esther Levy, Carolyn M. Jodka, Soumitra S. Ghosh, David G. Parkes, Richard A. Pittner, Lawrence J. D'Souza, John S. Ahn, Kathryn S. Prickett, Jonathan David Roth, Sean H. Adams
  • Hybrid Polypeptides with Selectable Properties
    Publication number: 20090286723
    Abstract: The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
    Type: Application
    Filed: August 11, 2006
    Publication date: November 19, 2009
    Applicant: AMYLIN PHARMACEUTICALS, INC.
    Inventors: Odile Esther Levy, Michael R. Hanley, Carolyn M. Jodka, Diana Y. Lewis, Christopher J. Soares, Soumitra S. Ghosh, Lawrence J. D'Souza, David G. Parkes, Christine M. Mack, Behrouz Bruce Forood
  • PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME
    Publication number: 20090186817
    Abstract: Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.
    Type: Application
    Filed: March 21, 2007
    Publication date: July 23, 2009
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Soumitra S. Ghosh, Josue Alfaro-Lopez, Lawrence J. D'Souza, Odile Esther Levy, Qing Lin, Christopher J. Soares
  • GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES
    Publication number: 20090036364
    Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
    Type: Application
    Filed: February 10, 2006
    Publication date: February 5, 2009
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Odile Esther Levy, Alain D. Baron, Lawrence J D'Souza, Mary Erickson, Soumitra S. Ghosh, Michael R. Hanley, Samuel Janssen, Carolyn M. Jodka, Diana Y. Lewis, Christine M. Mack, David G. Parkes, Richard A. Pittner, Christopher J. Soares, Ved Srivastava, Andrew A. Young
  • GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES
    Publication number: 20080312157
    Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
    Type: Application
    Filed: August 17, 2007
    Publication date: December 18, 2008
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Odile Esther Levy, Alain D. Baron, Lawrence J. D'Souza, Mary Erickson, Soumitra S. Ghosh, Michael R. Hanley, Samuel Janssen, Carolyn M. Jodka, Diana Y. Lewis, Christine M. Mack, David G. Parkes, Richard A. Pittner, Christopher J. Soares, Ved Srivastava, Andrew A. Young, Thao Le